Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Sarcoma 1

Conditions

Sarcoma, Kaposi 3Lymphoproliferative Disorders 3Epstein-Barr Virus Infections 3Multi-centric Castleman's Disease 2Lymphoma 2Acquired Immunodeficiency Syndrome 2Stomach Neoplasms 1Pyloric Stenosis, Hypertrophic 1Neoplasms 1Nasopharyngeal Carcinoma 1Macular dystrophy, corneal type 1 1Lymphoma, Extranodal NK-T-Cell 1Lymphadenopathy 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Immune Reconstitution Inflammatory Syndrome 1Hodgkin Disease 1Head and Neck Neoplasms 1HIV Infections 1Glioblastoma 1EBV Lymphomas 1Cytomegalovirus Infections 1Castleman Disease 1Brain Neoplasms 1

Interventions

Zidovudine 2Valganciclovir 2tocilizumab 1tanespimycin 1siltuximab 1liposomal doxorubicin 1Vincristine 1Sirolimus 1Rituximab 1Prednisone 1Interferon-alpha 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Etoposide 1Doxorubicin 1Cyclophosphamide 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Multi-centric Castleman's Disease × Valganciclovir × Clear all
NCT00092222 2026-06-01

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
75 enrolled
Lymphoid

Multi-centric Castleman's Disease, Macular dystrophy, corneal type 1, Lymphadenopathy, Lymphoproliferative Disorders, Neoplasms, HIV Infections

NCT01441063 2020-10-27

Tocilizumab for KSHV-Associated Multicentric Castleman Disease

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
8 enrolled 18 charts
LymphoidSarcoma

Multi-centric Castleman's Disease, Acquired Immunodeficiency Syndrome, Castleman Disease, Sarcoma, Kaposi

Data powered by HemOnc (CC BY 4.0) Colophon âš¡